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Abstract
Background: A carbohydrate-restricted (CR) diet can improve glycemic control in people with type 2 diabetes
mellitus (T2DM). There are concerns, however, that the high dietary fat content of CR diets can increase low-density
lipoprotein cholesterol (LDL-C), thus increasing cardiovascular disease (CVD) risk. Quantifying CVD risk associated
with changes in LDL-C in the context of CR diets is complicated by the fact that LDL-C reflects heterogeneous
lipids. For example, small LDL particle number (sLDL-P) is more closely associated with CVD risk than is total LDL-C,
and CR diets tend to decrease the proportion of sLDL-C in LDL-C, which standard lipid measures do not indicate.
Advanced lipoprotein assays, such as nuclear magnetic resonance (NMR) testing, can subfractionate lipoproteins by
size and density and may better depict the effects of CR diets on CVD risk.
Methods: Adults (N = 58) with T2DM (n = 37 women; baseline HbA1c ≥ 6.5%) completed a 6-month group-based
CR diet intervention. We obtained a standard lipid panel, advanced lipoprotein assays (NMR testing), and two 24-h
diet recalls at baseline and post-intervention (6 months). Participants also completed home-based blood ketone
testing (a biological index of dietary adherence) during the final five weeks of the intervention.
Results: From baseline to post-intervention, participants had increased mean HDL-C, decreased triglycerides and
triglyceride/HDL ratio, decreased mean sLDL-P, and increased LDL size, which reflect reductions in CVD risk
(ps < 0.05). Participants did not have statistically significant changes in total cholesterol, non-HDL-C cholesterol,
LDL-P, or HDL-P. Twelve participants (23.1%) had a ≥ 5% increase in sLDL-P. Exploratory analyses revealed that
participants with sLDL-P increases of ≥ 5% reported larger increases in servings of red meat than participants
without sLDL-P increases of ≥ 5% (+ 0.69 vs − 0.29 servings; p = 0.033). Changes in saturated fat intake were not
associated with changes in sLDL-P.
Conclusions: Among most participants, we observed changes in several lipid measures consistent with decreased
CVD risk. Approximately one in four participants evidenced increases in sLDL-P. Further research should clarify
whether individuals with increased sLDL-P after implementing a CR diet can reverse observed increases by limiting
red meat consumption.
Trial registration: ClinicalTrials.gov, NCT03207711, Registered 6/11/2017. Retrospectively registered.
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Introduction
Carbohydrate-restricted (CR) diets are a non-pharmaco-
logical intervention approach that can improve glycemic
control and reduce medication requirements in individ-
uals with type 2 diabetes mellitus (T2DM) [1]. CR diets
may be more effective in improving glycemic control
than low-fat diets [2–4]. CR diets for T2DM treatment
thus warrant further investigation, as the global diabetes
epidemic may affect more than 400 million individuals
worldwide [5].
Although CR diets have shown promise in improving
glycemic control for individuals with T2DM, researchers
have raised concerns regarding adverse effects of CR di-
ets on blood lipids, particularly low-density lipoprotein
(LDL-C) cholesterol levels [6]. Some data suggest that
CR diets, especially those that restrict carbohydrates
such that the body produces a low level of ketones
(“ketogenic diets”), can increase LDL-C levels [7],
though other data suggest that these increases may
normalize over time (i.e., 15 months [8]).
Elevated LDL-C has been associated with increased
CVD in epidemiological studies [9–11], and has also
been associated with greater consumption of red meat
[12, 13] and saturated fat [14, 15]. Greater red meat con-
sumption [16, 17] and, somewhat questionably, greater
saturated fat consumption [18–20] have also been asso-
ciated with increased CVD risk in epidemiological
studies. LDL-C has thus been proposed as a mechanism
linking red meat and saturated fat consumption with
CVD [21]. As a result, some dietary guidelines have
advocated reducing red meat and saturated fat
consumption to reduce CVD risk [22, 23]. CR diets
commonly involve increased red meat and saturated fat
consumption, which has raised concerns about the
effects of CR diets on CVD risk.
One of the challenges of assessing the impact of CR
diets on CVD risk is that LDL-C, as measured in stand-
ard lipid panels, does not yield information about het-
erogeneous sub-types that differ in their metabolic
origins and pathogenic roles. Advanced lipoprotein as-
says (nuclear magnetic resonance [NMR] lipid measures)
can separate the total LDL cholesterol into different sub-
types with differential associations with CVD risk. For
example, small dense LDL particles (sLDL-P) appear to
be particularly linked to greater CVD risk [24]. LDL par-
ticle number (LDL-P) and LDL particle size better pre-
dict CVD risk than the standard LDL-C measure [25].
Given similar total LDL-C levels, greater levels of sLDL-
P result in greater LDL-P. LDL-P may be particularly
helpful in improving accuracy of CVD risk prediction
among individuals with T2DM [26, 27]. Thus, advanced
lipoprotein testing that goes beyond the standard lipid
measure of LDL-C may better reflect the effects of
dietary interventions on CVD risk.
Recent research suggests that although CR diets may
increase total LDL cholesterol in some individuals, CR
diets tend to decrease the LDL particle number and shift
LDL particle subtypes away from sLDL-P [28]. Although
few studies have employed advanced lipid testing to clar-
ify the effects of CR diets on blood lipids, available data
suggest limited adverse effects of most CR diets on
blood lipids [29]. Thus, in the context of CR diets, in-
creased LDL-C may be offset in its effects on CVD risk
through shifts toward more favorable LDL subtypes and/
or metrics. To better define the effects of a CR diet on
lipids in T2DM, we examined changes in both a standard
lipid panel and an advanced lipoprotein assay among
individuals in a trial testing behavioral approaches to




We randomized participants in a 1:1 ratio to one of two
group-based 3-month in-person nutritional and behav-
ioral intervention arms and followed participants for a
3-month post-intervention period (6 months of study
participation total). Both arms received CR diet instruc-
tion, but one arm also received mindful eating training.
We recruited three waves of approximately 20 partici-
pants each (N = 58 total). Participants provided blood
specimens (LabCorp, Inc. location of choice) and also
completed other assessments not included in these ana-
lyses. The University of California, San Francisco (UCSF)
Institutional Review Board approved all study proce-
dures. All participants provided written informed con-
sent prior to enrollment. See Mason and colleagues [30]
for further trial details.
Participants
We recruited participants from several sources. We sent
letters about the study to patients with T2DM who have
been seen in UCSF clinics, posted flyers in the commu-
nity, and posted ads on social media websites such as
Facebook, Nextdoor, and Craigslist. Participants were 18
years of age or older; had a diagnosis of T2DM (6.5% ≤
HbA1c < 12.0% confirmed by blood test at screening);
were not lactating, < 6months postpartum, pregnant, or
planning to become pregnant in the next 6 months; had
not had bariatric surgery in the prior 18 months;
reported no substance misuse, medical issue, or other
health conditions that would make it difficult to partici-
pate; did not follow vegan or vegetarian dietary patterns;
owned and used a smartphone; were willing to complete
the study regardless of randomization arm; and endorsed
experiencing food cravings several times per week. See
Mason and colleagues [30] for more detailed inclusion
and exclusion criteria related to behavioral measures.
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Interventions
Participants in both arms completed 12 weekly in-per-
son sessions followed by 3 monthly in-person mainten-
ance sessions, for a total of 15 sessions over 6 months.
Carbohydrate-restricted (CR) diet instruction
Participants in both arms received identical instruction
in following a CR diet, similar to that in our previously
published work, from the same group leader [31, 32].
We instructed participants to reduce their carbohydrate
intake to between 20 and 35 non-fiber grams of carbo-
hydrates per day (with the goal of remaining under 50
non-fiber grams per day), to eat an adequate amount of
protein (as described by the Institute of Medicine) [33],
and to eat fat to satiety. We advocated a gradual transi-
tion towards this CR diet over the first three weeks of
the intervention by instructing participants to change
their breakfasts and snacks in the first week, lunches in
the second week, and dinners in the third week. After
about 4 weeks, participants were instructed to be fully
implementing the prescribed CR diet. The specific con-
tent of participants’ diets varied, but generally included
green leafy and other non-starchy vegetables, avocados,
nuts, seeds, oils (except trans fats), butter, fish, poultry,
meats, eggs, cheese, and low-carbohydrate fruits such as
strawberries and blackberries. We instructed participants
to avoid sugar-sweetened foods (e.g., desserts such as
cakes, cookies, and ice cream), sugar-sweetened bever-
ages, naturally sweet foods (e.g., tropical fruits), and
starchy foods (e.g., foods made with grain-based flours
such as bread, pasta, tortillas, breakfast cereals, and
pastas, as well as potatoes and rice). We also noted evi-
dence of the association of red-meat consumption with
some cancers, and suggested approaches to implement-
ing a CR diet without relying on red meat. A board-cer-
tified internal medicine physician who has transitioned
patients with T2DM onto CR diets in her private prac-
tice led the CR diet instruction.
Mindful eating training
Participants randomized to the mindful eating arm re-
ceived mindful eating training in addition to the CR diet
classes. We delivered mindful eating training in the form
of a smartphone application that contained 28 video
modules and instructed participants to watch two or
three modules per week. These modules focused on
mindful eating topics including breaking the automatic
eating habit loop and coping with food cravings without
eating. Participants who received the mindful eating
training attended weekly hour-long sessions with a
mindful eating teacher who answered questions and led
discussions about module content (see [30] for details).
As all participants received identical CR diet instruction,
which we hypothesized to be the primary driver of
changes in lipid profiles among participants, we com-
bined both intervention arms for the current analyses.
We confirmed that changes in lipid measures did not
differ by intervention group.
Measures
We collected demographic information, diabetes-re-
lated information, anthropometric data, standard
lipid panels, and NMR lipoprotein assays from all partic-
ipants. We assessed participants’ HbA1c, fasting blood
glucose, and fasting blood insulin using standard
procedures at a Clinical Laboratory Improvement
Amendments certified clinical laboratory (LabCorp,
Inc.). Participants self-reported exogenous insulin use
and years since T2DM diagnosis. We assessed partic-
ipants’ weight using a digital scale and height using a
wall-mounted stadiometer (Doran Scales, Inc., Model
DS1100). We computed body mass index (BMI) from
these assessments.
Lipid assays
We used the NMR LipoProfile III assay (LabCorp, Inc.)
to assess sLDL-P, LDL-P, average LDL particle size,
HDL-P, and the lipoprotein insulin resistance (LP-IR)
index. This assay produces results from lipoprotein par-
ticle analysis using nuclear magnetic resonance (NMR)
spectroscopy (400MHz) [34]. We examined the follow-
ing measures collected or computed from a standard
lipid panel (LabCorp, Inc.): triglycerides, LDL-C, HDL-
C, non-HDL cholesterol, and triglycerides/HDL ratio.
Blood ketones
In week 4, we provided participants with a home-based
blood ketone monitoring device (Precision Xtra® System;
Abbott Diabetes Care, Alameda, California) and ketone
strips. Participants used these supplies to measure β-
hydroxybutyrate (BOHB) [35] in their blood. We taught
participants how to use the monitoring device in person
and asked them to measure their blood ketones before
dinner, two to three times a week, on alternating days.
Participants reported ketone measurements via an online
survey on a weekly basis. The ketone monitoring devices
store data, which staff checked at every weekly class
(starting in week 5) and every monthly class (starting at
month 4) to confirm self-reported measurements. We
defined our target BOHB level as between 0.3 and 3.0
mmol/L. Although the level of carbohydrate restriction
needed to achieve ≥0.3 BOHB varies between individ-
uals, most individuals need to restrict to fewer than 50 g
per day of non-fiber carbohydrate to achieve this blood
ketone range [36]. For the current analyses, we used
ketone data from the final five weeks of the 6-month
study period.
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Dietary intake
We collected 24-h recalls from participants via tele-
phone using the University of Minnesota’s Nutrition
Data System for Research (NDSR, Nutrition Coordinat-
ing Center, University of Minnesota) software. This is a
widely used dietary analysis program that can assess a
wide variety of foods. Although some recommendations
suggest that a single 24-h assessment at each timepoint
is adequate for longitudinal assessments in a clinical
trial, we collected two assessments at each timepoint
(baseline, 3 months, and 6 months) to increase accuracy
(one on a weekday and one on a weekend day) [37].
Trained research assistants conducted the dietary recalls,
which we conducted without prior notification (to avoid
changes in diet on the reporting day). We averaged data
across the two days of recalls. We conservatively defined
implausible energy intakes as < 500 or ≥ 5000 kcal/day
and excluded these recalls from analysis. We adjusted
foods for total energy using the residual method and the
population average total energy intake at each timepoint
[38]. We adjusted nutrients for total energy intake using
the density method. We used the following foods and
nutrients in analyses: red meat (beef, veal, pork, and
lamb), processed meat including red processed meat
(ham, bacon, sausage, hot dog, and cold cuts) and white
processed meat (turkey sausages and hot dogs, and
poultry cold cuts), red and processed meats combined,
and percentage of daily calories from saturated fat.
Analytic plan
First, we computed descriptive statistics as means and
standard deviations or counts and percentages. Second,
we computed two-sided paired-samples t-tests compar-
ing lipids measures at baseline and at post-intervention.
We report means at each timepoint, mean changes from
baseline, 95% confidence intervals, and p-values. We
used p < 0.05 as our criterion for statistical significance.
Third, we assessed the sensitivity and specificity of
standard lipid panel measures (LDL-C, triglyceride/
HDL-C ratio, and non-HDL cholesterol [25, 39]) to
detect participants with increases of 5% or greater
(≥5%) in sLDL-P, and used standard equations for these
measures [40]. We set an increase of ≥ 5% as a value that
exceeded the typical coefficient of variation of the sLDL-
P assay [41], which therefore likely reflected a real and
meaningful increase (rather than assay variation).
Fourth, we compared participants with, versus
without, increases in sLDL-P of ≥5% in terms of dietary
adherence, dietary intake, and exogenous insulin use
[41]. Because (1) the group with increases of ≥5% in
sLDL-P included fewer than 20 participants, (2) the
number of participants was not balanced between
groups, and (3) we were comparing values that were not
normally distributed, we used non-parametric tests
(Mann-Whitney U-test and Spearman rank correlation)
for these comparisons [42]. We investigated dietary ad-
herence as indexed by blood ketone measures collected
during the final 5 weeks of the study. We considered
“adherent” to be at least two-thirds of assessments of
BOHB values being ≥0.3 (we required a minimum of
three measurements to compute adherence), and “non-
adherent” to be fewer. We operationalized exogenous in-
sulin use as “use” versus “non-use” of any type of insulin
at 6 months. We examined changes in dietary intake var-
iables from baseline to 6 months.
Finally, we assessed whether there were differences in
the proportion of participants with and without
increases in sLDL-P based on whether they were using
statins or other lipid-lowering agents at baseline using
Fisher’s Exact Test.
Results
Participant characteristics and data Descriptives
We enrolled 58 participants. On average, participants
were 58.7 years of age and had been diagnosed with
T2DM for 8.7 years. Most met criteria for overweight or
obesity, with an average BMI of 32.2 (Table 1). Fifty per-
cent of participants reported race/ethnicities other than
non-Hispanic white, and 63.8% were female. At baseline,
8 (21.6%) female participants were pre-menopausal and
29 (78.4%) female participants were menopausal. At
baseline, participants consumed an average of 205.03
(SD = 97.52) grams carbohydrates [41.68% (SD = 10.18%)
of dietary calories]. More specifically, at baseline, partici-
pants consumed an average of 184.97 (SD = 91.63) grams
Table 1 Participant characteristics
Characteristic N = 58
Age, years; M (SD) 58.7 (10.9)





Asian/Pacific Islander; % 20.7
Other; % 8.6
Years with T2DM; M (SD) 8.7 (7.2)
BMI, kg/m2; M (SD) 32.2 (6.3)
Weight, kg; M (SD) 92.0 (21.1)
HbA1c, %; M (SD) 7.7 (1.3)
Fasting Glucose (Plasma)a, mg/dL; M (SD) 153 (46)
Fasting Insulin*, μIU/mL; M (SD) 17.7 (11.8)
Note. T2DM = type 2 diabetes mellitus; BMI = body mass index; HbA1c =
glycosylated hemoglobin A1c
aWe omitted one observation from each of fasting glucose and insulin as
these were not fasting specimens
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non-fiber carbohydrates [38.40% (SD = 9.92%) of dietary
calories]. After implementation of the CR diet, at 6
months, participants consumed an average of 93.58
(SD = 94.86) grams carbohydrates [19.49% (SD = 11.74%)
of dietary calories]. More specifically, at 6 months, par-
ticipants consumed an average of 77.43 (SD = 90.07)
grams non-fiber carbohydrates [16.93% (SD = 11.49%) of
dietary calories].
Three participants dropped out of the study, leaving
n = 55 who completed the intervention. An additional
two participants provided non-fasting blood samples
(one participant at baseline, one participant at 6
months). The former participant did not provide a sam-
ple at 6 months and was therefore not included in ana-
lyses involving change in lipid measures. We omitted
some of the retained non-fasted participant’s data from
analyses; specifically, we omitted changes in triglycerides
and glucose (as well as baseline insulin value reported in
Table 1) as these measures are impacted by fasting sta-
tus [43, 44]. Inclusion of this participant did not, how-
ever, change the patterns of directionality or statistical
significance of results. Laboratory error caused one par-
ticipant to be missing a standard lipid panel at baseline
and another participant to be missing a standard lipid
panel at 6 months. On average, participants provided 8.0
(SD = 3.8) blood ketone measurements over the final five
weeks of the study period. Six of the 52 (11.5%) partici-
pants in primary analyses reported in Table 2 did not
provide sufficient ketone measurements (in one case,
zero samples due to fingerstick aversion) for blood
ketone analyses. Overall, two participants who com-
pleted the intervention were missing the 6-month 24-h
diet recall data: One was missing due to travel, and other
was missing due to implausible energy intake. An
additional two participants (who we included in
analyses of 6-month 24-h diet recall data) did not
contribute baseline 24-h diet recall data: One was
missing due to implausible energy intake, and the
other due to missing data. See tables for sample sizes
for each analysis.
Changes in lipid measures
Changes in standard lipid panel measures
From pre- to post-intervention, we observed statistically
significant increases in HDL-C and statistically signifi-
cant decreases in triglycerides and the triglyceride/HDL-
C ratio on standard lipid panel testing (Table 2). These
changes reflect favorable changes in CVD risk. Although
total cholesterol increased an average of 7 mg/dL, this
change did not reach statistical significance. There was
no evidence of meaningful change in non-HDL-C
cholesterol.
Changes in NMR lipoprotein assay measures
From pre- to post-intervention, we observed statistically
significant decreases in sLDL-P and statistically sig-
nificant increases in LDL size (Table 2). These
changes reflect favorable changes in CVD risk. There
were not statistically significant changes in LDL-P
and HDL-P.
Table 2 Change in standard lipid and NMR LipoProfile (LabCorp) from baseline to 6 months
Source of lipid
measure








95% CI [LB, UB] P
Standard LDL-C mg/dL 92.86 (38.56) 99.89 (36.51) 7.03 (29.93) 53a [−1.22, 15.28] .093
Standard HDL-C mg/dL 52.79 (16.95) 56.49 (16.97) 3.70 (8.54) 53a [1.34, 6.05] .0027
Standard Cholesterol, Total mg/dL 176.96 (43.23) 179.83 (44.14) 2.87 (34.30) 53a [−6.59, 12.32] .55
Standard Triglyceride mg/dL 154.08 (78.25) 117.63 (53.57) −36.44 (59.64) 52a,b [−53.05, −19.84] .0001
Standard Triglyceride/HDL-C ratio 3.49 (2.59) 2.38 (1.52) −1.11 (1.70) 52a,b [−1.58, −0.64] <.0001
Standard Non-HDL-C cholesterol mg/
dL
124.17 (41.92) 123.34 (37.84) −0.83 (33.22) 53a [−9.99, 8.33] .86





NMR LDL-P nmol/L 1253.04 (430.16) 1246.60
(404.76)
−6.44 (359.33) 55 [−103.58, 90.70] .89
NMR LDL Size nm 20.58 (0.61) 20.82 (0.59) 0.24 (0.46) 55 [0.12, 0.37] .0003
NMR HDL-P (Total) μm/L 33.62 (7.07) 34.17 (6.54) 0.56 (4.53) 55 [−0.67, 1.78] .36
Note. LDL-C = calculated low-density lipoprotein cholesterol, HDL-C = calculated high-density lipoprotein cholesterol, Non-HDL-C cholesterol computed as (total
cholesterol – HDL-C), sLDL-P = small low-density lipoprotein number, LDL-P = low-density lipoprotein number, LDL size = low-density lipoprotein size; HDL-P
(total) = total high-density lipoprotein number
aAnalysis omits one participant who was missing a baseline standard lipid panel and one participant who did not provide a standard lipid panel at 6 months
(n = 2 omitted)
bAnalysis omits participant who provided a non-fasting sample at baseline (n = 1 omitted). The pattern and statistical significance of results remains if we retain
the non-fasted participant
t-test p-value is two-sided. LB = Lower bound, UB=Upper bound
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Sensitivity and specificity of standard lipid panel
measures to detect changes in sLDL-P
Of the 52 participants who provided fasting samples at
baseline and 6months, 29 (55.8%) experienced LDL-C
increases of ≥5%, and 12 (23.1%) experienced changes in
sLDL-P of ≥5%. Overall, standard lipid panel measures
tended to achieve low sensitivity and specificity to iden-
tify participants with or without increases in sLDL-P of
≥5%, respectively (Table 3).
Subgroup analyses: increases (5% or greater) in sLDL-P
We next compared participants with and without ≥5%
increases in sLDL-P (Table 4) to assess possible factors
associated with these increases. We did not find statistically
significant differences across these groups in saturated fat
intake at 6months or in changes in saturated fat intake
from baseline to 6months. Participants with ≥5% increases
in sLDL-P tended to increase their red meat consumption
(median change, + 0.69 servings per day), while those
without such an sLDL-P change decreased their red meat
consumption (median change, − 0.29 servings per day).
This difference was statistically significant between these
groups (p = 0.033, Mann-Whitney U; Table 4). There was
no significant difference in processed meat consumption
between these groups.
To further examine associations between changes in
dietary intake (of saturated fat and red meat) and change
in sLDL-P, we assessed whether there was evidence of
dose-response associations (using Spearman rank corre-
lations; Table 5). There were no statistically significant
associations between sLDL-P and changes in saturated
fat intake. Notably, there was a statistically significant
positive correlation (rho = 0.615, p=0.04) between in-
creases in red meat consumption and increases in sLDL-
P in the group with ≥5% increases in sLDL-P. In con-
trast, there was little evidence of a correlation between
red meat consumption and sLDL-P in the remaining
participants (rho=-0.066, p=0.69). We did not observe
any statistically significant correlations between pro-
cessed meat consumption and sLDL-P.
There were no statistically significant differences in
dietary adherence as assessed using blood ketone mea-
surements between those with (M = 44.6% adherent,
SD = 38.3%, n = 10) and those without (M = 60.0% adher-
ent, SD = 32.7%, n = 36) ≥5% increase in sLDL-P. Of
participants with ≥5% increases in sLDL-P at 6
months who provided sufficient blood ketone measure-
ments (n = 10), 30.0% were in ketosis at more than
two-thirds (66.6%) of measurements at 6 months
(95% CI: 6.7 to 65.2%). Of participants without ≥5%
increases in sLDL-P (n = 36), 47.2% were in ketosis at
more than two-thirds of measurementsat 6 months
(95%CI: 30.4 to 64.5%). We had insufficient ketone
measurements (two or fewer measurements at 6
months) for 16.7% (2/12) of participants with ≥5% in-
creases in sLDL-P, and for 10.0% (4/40) of partici-
pants without ≥5% increases in sLDL-P. Of the 12
participants with sLDL-P increases of 5% or greater, 1
(8.3%) was using exogenous insulin. Of the 40 partici-
pants without such increases, 5 (12.5%) were using
exogenous insulin. This difference was not statistically
significant (Fisher’s Exact p = 1.00).
We also assessed the association between statins and
other lipid-lowering agents with changes in sLDL-P.
Sixty-seven percent of participants with and without
≥5% increases in sLDL-P were using lipid-lowering
agents at baseline. One of these participants (who did
not have a ≥5% increase in sLDL-P) was taking fenofibri-
ate, and the remainder were taking statins. At 6 months,
among participants without a ≥5% increase in sLDL-P,
five (17%) had decreased or stopped taking lipid-lower-
ing agents (all changes were in statins). In the group
with a ≥5% increase in sLDL-P, three (37%) decreased or
stopped statins (p = 0.33, Fisher’s exact test). Two partic-
ipants in the group without a ≥5% increase in sLDL-P
increased their statin dose, compared to none of the
participants with a ≥5% increase in sLDL-P (p = 1.00).
Discussion
In these analyses, we sought to clarify the impact of a
carbohydrate-restricted (CR) diet on both standard
lipid panel measures and advanced lipoprotein
assay measures in people with T2DM. Previous data
have shown that relative to a standard LDL-C measure,
advanced lipoprotein assay measures may provide met-
rics that more accurately predict CVD risk [25]. Overall,
our data suggested that implementing a CR diet in the
context of T2DM is associated with lipid profile changes
that correlate with lower CVD risk. Overall, we observed
statistically significant increases in HDL and LDL size,
and statistically significant decreases in triglycerides, the
triglyceride/HDL-C ratio, and sLDL-P. In contrast, more
Table 3 Sensitivity and specificity of standard lipid panel measures to identify individuals at greater or lesser risk for worsened sLDL-P
Lipid measure (5% Δ) ≥5% Δ sLDL-P
Sensitivity % [TP/(TP + FN)]; [95% CI]
<5% Δ sLDL-P
Specificity % [(TN/(TN + FP)]; [95% CI]
LDL-C 58.3% (7/12); [27.7, 84.8] 45.0% (18/40); [29.3, 61.5]
Triglyceride/HDL-C Ratio 6/12 (50.0%); [21.1, 78.9] 85.0% (34/40); [70.2, 94.3]
Non-HDL-C Cholesterol 58.3% (7/12); [27.7, 84.8] 60.0% (24/40); [43.3, 75.1]
Note. Δ = Change from baseline to 6 months computed as (6 months minus baseline); TP = true positive, FN = false negative, TN = true negative, FP = false positive
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than half of participants (55.8%) had increases in LDL-C.
Advanced lipoprotein assay measures indicated that
23.1% [12] participants had an increase in sLDL-P of 5%
or greater. Taken together, our data suggest that most
people implementing a CR diet experience improved
lipid profiles, but a minority may not, and may instead
have increases in lipid parameters associated with CVD
risk. Whereas most participants in our sample evidenced
increases in the standard lipid panel measure of LDL-C,
the advanced lipoprotein assay measures suggested that
these increases did not accurately represent the effects
of the CR diet on lipid-related CVD risk.
A variety of mechanisms may explain patterns of
change in LDL subclass concentrations in the context of
a CR diet. Our data suggest that CR diet composition
may impact these patterns, and add to previous research
showing that red meat (particularly beef) consumption
may impact lipoproteins in the context of carbohydrate
restriction [45]. Genetic factors, which we did not assess
in this trial, may represent another factor that may in-
fluence these patterns. Furthermore, there may be an
interaction between diet composition and genetic predis-
positions that dictates patterns of change in LDL sub-
types. In our data, we found evidence that increasing red
meat consumption was associated with increases in
sLDL-P, though increasing saturated fat was not associ-
ated with these increases. These findings are consistent
with other data showing improvements in several ad-
vanced lipoprotein measures in CR diets regardless of
saturated fat content (e.g., CR diets with lower and
higher levels of saturated fat content), relative to higher
carbohydrate diets [46]. In a subset of our participants
with increased sLDL-P, there was evidence of a mono-
tonic (dose-response) association between changes in
red meat consumption and changes in sLDL-P. Evidence
for a dose-response association between red meat con-
sumption and sLDL-P was weak in the participants with-
out increased sLDL-P. Though very preliminary, these
data support a model in which some people experience
increased sLDL-P with increased red meat consumption
during a CR diet, whereas others do not. Further re-
search should replicate this finding, and, if reflective of a
true process, identify potential genetic or other factors
responsible for this sensitivity to red meat consumption.
In addition, further research should identify what aspects
of red meat consumption influence the increases in
sLDL-P we observed. Though there has been concern
about the effects of saturated fat intake on lipid-related
CVD risk, we did not find evidence that saturated fat in-
take or increases in saturated fat intake were associated
with increases in sLDL-P. This suggests that our ob-
served association between red meat consumption and
sLDL-P may be related to other factors, such as the
precise types of fat in red meat, aspects of protein
components, or other factors. We also assessed whether
there was an association between adherence to
Table 4 Twenty-four diet recall measures of saturated fat, red meat, and processed meat intakes at 6 months and change from
baseline across participants with and without sLDL-P increases of 5% or greater
Dietary measure ≥5% Δ sLDL-P
Median (IQR) n = 11
<5% Δ sLDL-P
Median (IQR) n = 40–42^
Z-value (Wilcoxon) p-value Median (IQR) Diff
Value at 6 months
Saturated fat density 17.81 (14.95 to 25.40) 19.33 (16.75 to 25.20) n = 42 −0.790 .43 1.68 (−4.10 to 8.12)
Red and processed meat, servings/day 2.84 (1.57 to 5.24) 2.11 (1.13 to 3.76) n = 42 0.965 .33 −0.77 (−2.92 to 1.36)
Red meat, servings/day 2.14 (0.29 to 2.93) 0.44 (0.15 to 2.27) n = 42 1.382 .17 −0.72 (−2.42 to 0.56)
Processed meat, servings/day 0.72 (0.23 to 2.93) 1.12 (0.29 to 1.76) n = 42 0.066 .95 −0.02 (−1.30 to 1.00)
6-month change
Saturated fat density 6.73 (3.93 to 11.75) 5.63 (2.04 to 14.41) n = 40 0.160 .87 −0.57 (−7.02 to 8.87)
Red and processed meat, servings/day 1.22 (−0.01 to 3.28) 0.26 (−1.63 to 1.70) n = 40 1.626 .10 −1.29 (−3.90 to 0.80)
Red meat, servings/day 0.69 (−0.26 to 2.06) −0.29 (−1.28 to 0.74) n = 40 2.130 .033 −1.15 (−3.18 to 0.17)
Processed meat, servings/day 0.42 (−0.24 to 1.88) 0.35 (−0.53 to 1.41) n = 40 0.275 .78 −0.20 (−1.59 to 1.19)
Note. Change from baseline to 6 months computed as (6 months – baseline). ^ Variation in sample size between 40 and 42 is due to missing data: One participant
had baseline diet recall data omitted to due to an implausible energy intake, and another had missing baseline diet recall data (see Analytic Plan and Results
sections). Red meat, red and processed meat, and processed meat variables were energy-adjusted (see Methods)
Table 5 Spearman rank correlations of change in small LDL-P
with change in dietary measure from baseline to 6 months
Diet measure Spearman rho p-value 95% CI around rho
Participants with ≥5% increase in small LDL-P at 6 months (n = 11)
Saturated fat, % calories −0.200 .55 (−0.714, 0.454)
Red meat 0.615 .044 (0.024, 0.887)
Processed meat 0.123 .72 (−0.515, 0.673)
Participants with <5% increase in small LDL-P at 6 months (n = 40)
Saturated fat, % calories 0.000 1.00 (−0.311, 0.312)
Red meat −0.066 .69 (−0.370, 0.251)
Processed meat −0.012 .94 (−0.323, 0.300)
Note. Red meat and processed meat variables are energy-adjusted (see Methods)
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carbohydrate restriction (using blood ketones as a bio-
logical marker of dietary adherence) and lipid measures
and did not find this index of dietary adherence to be
associated with lipid changes.
Although these data should be considered preliminary,
they may hold potential implications for clinical practice.
First, our data suggest that it may be useful to use ad-
vanced lipoprotein assay measures to assess the effects
of a CR diet on more precise lipid measures, and to con-
sider using these measures to adjust diet composition. In
particular, assessing changes in LDL particle number
and sLDL-P may be helpful in assessing the potential ef-
fects of a CR diet composition on an individual’s CVD
risk, and therefore helpful in fine-tuning diet recommen-
dations. We believe that there are several challenges in
making clinical practice recommendations based upon
advanced lipoprotein assays in the CR diet context. For
example, availability of different advanced lipid testing
assays differs by practice setting, and results have not
been fully standardized across assays. This study did not
compare assays, and existing data are limited in regard
to whether particular versions of advanced lipoprotein
assays should be recommended. In practice, clinicians
may currently need to rely on assays available at a single
laboratory. The implications of advanced lipoprotein
assay testing for dietary recommendations would benefit
from further confirmation. Reducing red meat consump-
tion might be advised for people with elevated sLDL-P.
In the absence of clinical trial data supporting such a
practice, however, this remains a hypothesis to be tested
rather than a practice that can be clearly recommended.
Our data suggest that practitioners consider the poten-
tial impacts of increasing red meat consumption on
CVD risk when suggesting dietary regimens, such as CR
diets. Importantly, most of our study participants re-
duced rather than increased red meat consumption,
demonstrating the feasibility of implementing a CR diet
without increasing red meat consumption.
Our results differ from those reported by Chiu, et al.,
which found that increased small LDL particles corre-
lated with increased saturated fat consumption in a
crossover study design [47]. Several differences in study
design may account for at least some of these discrepant
findings. First, we used a different advanced lioprotein
assayp (NMR LipoProfile) that is widely accessible but,
tends to differ somewhat in results from the methods
used by Chiu and colleagues [48]. Second, Chiu and
colleagues’ sample was primarily male (85%), whereas
ours was primarily female (64%). Third, the sources of
saturated fats in the Chiu study were primarily dairy fats,
whereas the sources of saturated fat may have been
more variable in our study. Fourth, our CR diet pre-
scribed a substantially smaller carbohydrate intake, and
it is possible that carbohydrate intake influences the
effects of saturated fat consumption on LDL subclasses.
We are aware of one other clinical trial that has exam-
ined LDL subclasses in the context of a CR diet in
T2DM [29]. Data from that study revealed a similar pat-
tern to that observed in our data. On average, data from
both trials indicated significant increases in HDL and
LDL size, and statistically significant decreases in triglyc-
erides, the triglyceride/HDL-C ratio, and sLDL-P. Of
Fig. 1 Note. Figure depicts percent change from pre- to post-intervention in lipid measures
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note, both trials also found increases in LDL-C; however,
these increases were not statistically significant in our
trial. Thus, findings from our trial replicate earlier find-
ings suggesting that CR diets may improve lipid parame-
ters for many people with T2DM.
Limitations
An important limitation is that our data did not allow
us to examine large particle LDL sub-classes in detail.
Although large LDL (relative to small LDL) may gen-
erally be associated with lower CVD risk, some forms
of large LDL may have significant atherogenic poten-
tial [24]. In our results, we note that although sLDL-
P decreased on average, the total LDL-P number did
not decrease as much as sLDL-P. This indicates that
on average, larger LDL-P increased. At a minimum,
we emphasize caution about drawing too much re-
assurance from the finding of declines in sLDL-P.
Furthermore, as in most diet patterns studied among
people with T2DM, there are relatively few long-term
data about the long-term impact of CR diets [49].
One study that followed patients with T2DM for 44
months did not find evidence of negative cardiovascu-
lar effects [50].
This study should be interpreted cautiously for other
reasons. Our sample was small, and these findings
require replication using larger samples with adequate
power. Although promising, advanced lipid measures
represent surrogate markers of CVD risk. A controlled
trial with clinical endpoints would clarify the extent to
which a CR diet impacts CVD risk, though this would
require significant time and resources.
Although this study used the widely available NMR
Lipoprofile, such testing is limited because it lacks
standardization and comparability of information
provided by other forms of advanced lipoprotein assays
[51]. For example, after finding that different advanced
lipid measurement methods yielded differential non-
HDL-P values, Delatour and colleagues [48] recently
called for standardizing these methods by use of a com-
mon commutable calibrator to improve cross-platform
comparability.
A final limitation is that we used data from a clinical
trial of a nutritional intervention in which participants
were free to choose different foods and monitored their
own carbohydrate intake. Although this represents a
real-world test of what occurs when restricting carbo-
hydrate intake, our participants' exact nutritional intake
was much more variable than that in a controlled
feeding study.
Conclusions
These analyses, in tandem with those reported following
a similar CR protocol [29], provide some evidence that
for most people with T2DM, a CR diet is associated with
favorable changes in lipid profiles (in this case, over a 6-
month period). These data further support the applica-
tion of caution in the interpretation of conventional
standard lipid panel measure results (i.e., LDL-C) among
people with T2DM who follow a CR diet and suggest
possible advantages of advanced lipoprotein assays to
monitor effects of CR diets on lipid-related CVD risk
factors. Some people with T2DM who begin a CR diet
appear to have increases in LDL subtypes associated
with CVD risk (i.e., sLDL-P). For these individuals, red
meat consumption may play a meaningful role in in-
creases in sLDL-P. Future work to standardize advanced
lipoprotein assay methods may facilitate the use of these
methods in clinical practice. Finally, additional research
should extend these findings to clinical endpoints so as
to quantify actual clinical risk associated with CR diets
for individuals with T2DM (i.e., CVD events).
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